HENDERSON, Nev.--(BUSINESS WIRE)--With more and more Canadians becoming hooked on prescription opioids, the federal government in Ottawa has started to consider limits and prescription monitoring programs to curb the growing abuse. Rainbow Coral Corp. (RBCC) has been actively engaged in discussions with potential Canadian partner companies and medical groups to expand the distribution of Naltrexone, an anti-opioid abuse treatment, in the country to help combat this situation.
As a result of the growing problem, opioid-related deaths have climbed in several Canadian provinces and opioid overdoses have become one of the leading killers of young Canadians. In Ontario alone, such deaths spiked nearly 20 percent over a four-year period, and now average about 10 accidental deaths per week. Canada ranks second only to the U.S.in per capita consumption of prescription opioids.
Opioids are powerful drugs often prescribed used to manage pain. One regrettable side effect is that these drugs can lead to physical and psychological dependence and addiction, especially when used for a long duration.
“It’s unfortunate that drugs that are supposed to relieve pain are now themselves causing suffering and death,” said RBCC CEO Kimberly Palmer. “RBCC and its partners can help in resolving this addiction and abuse problem with Naltrexone – a treatment that has been proven to successfully curb opioid addiction and dependence. We’re currently nearing agreements with a Canadian medical group that utilizes Naltrexone to treat substance abuse and with another company to distribute Naltrexone in Canada. These efforts should assist in relieving the problem, but more work remains to be done.”
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.